Virus-Immunotherapy combo shows promise against tough cancers
Disease control
Ongoing
This study tests a cancer-killing virus (VSV-IFNβ-NIS) combined with an immunotherapy drug (pembrolizumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective dose …
Phase: PHASE1, PHASE2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC